Relevance of genotyping non-small-cell lung cancer patients on response to platinum-basedchemotherapy and tyrosine kinase inhibitors

被引：0
|
作者：
Campos-Parra, Alma D.
Cruz, Graciela
Zuloaga, Carlos
Aviles, Alejandro
Manriquez, Maria E. Vazquez
Borbolla-Escoboza, Jose R.
Cardona, Andres
Abelardo, Meneses
Arrieta, Oscar
机构：
来源：
CLINICAL CANCER RESEARCH | 2012年 / 18卷 / 03期
关键词：
D O I：
10.1158/1078-0432.12AACRIASLC-B3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B3
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
    Murray, Samuel
    Karavasilis, Vasilios
    Bobos, Mattheos
    Razis, Evangelia
    Papadopoulos, Savvas
    Christodoulou, Christos
    Kosmidis, Paris
    Fountzilas, George
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2012, 31
  • [2] Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
    Samuel Murray
    Vasilios Karavasilis
    Mattheos Bobos
    Evangelia Razis
    Savvas Papadopoulos
    Christos Christodoulou
    Paris Kosmidis
    George Fountzilas
    Journal of Experimental & Clinical Cancer Research, 31
  • [3] Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
    Santarpia, Mariacarmela
    Altavilla, Giuseppe
    Salazar, Maria F.
    Magri, Ignacio
    Pettineo, Giuseppe
    Benecchi, Sara
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2011, 5 (03) : 413 - 424
  • [4] Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Yao, Yu
    Yang, Huaping
    Zhu, Bo
    Wang, Song
    Pang, Jiaohui
    Wu, Xiaoying
    Xu, Yang
    Zhang, Junli
    Zhang, Jinfeng
    Ou, Qiuxiang
    Tian, Hui
    Zhao, Zheng
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [5] Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Yu Yao
    Huaping Yang
    Bo Zhu
    Song Wang
    Jiaohui Pang
    Xiaoying Wu
    Yang Xu
    Junli Zhang
    Jinfeng Zhang
    Qiuxiang Ou
    Hui Tian
    Zheng Zhao
    Respiratory Research, 24
  • [6] Second-generation tyrosine kinase inhibitors in non-small-cell lung cancer
    Herbst, Roy S.
    CLINICAL LUNG CANCER, 2007, 8 : S50 - S51
  • [7] Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Santarpia, Mariacarmela
    Gil, Nuno
    Rosell, Rafael
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (04) : 461 - 477
  • [8] Predictive signature of response to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer cells by tyrosine kinase activity profiling
    Izawa, Naoki
    Serizawa, Masakuni
    Naji, Faris
    de Wijn, Rik
    Hilhorst, Riet
    Ruijtenbeek, Rob
    Yasui, Hirofumi
    Nakajima, Takako
    Boku, Narikazu
    Koh, Yasuhiro
    CANCER RESEARCH, 2014, 74 (19)
  • [9] Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
    Zucali, P. A.
    Ruiz, M. G.
    Giovannetti, E.
    Destro, A.
    Varella-Garcia, M.
    Floor, K.
    Ceresoli, G. L.
    Rodriguez, J. A.
    Garassino, I.
    Comoglio, P.
    Roncalli, M.
    Santoro, A.
    Giaccone, G.
    ANNALS OF ONCOLOGY, 2008, 19 (09) : 1605 - 1612
  • [10] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
    Liao, Bin-Chi
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Chen, Ya-Fang
    Chang, Chin-Hao
    Ho, Chao-Chi
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) : 1754 - 1761
12345